RT Journal Article
T1 The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
A1 Bishton, Mark
A1 Marshall, Scott
A1 Harchowal, Jatinder
A1 Salles, Gilles
A1 Golfier, Camille
A1 Tucci, Alessandra
A1 Fernández, Alicia Rodriguez
A1 Sanchez Blanco, Jose Javier
A1 Bocchia, Monica
A1 Kim, SooKyoung
A1 Lee, Young Nam
A1 Zinzani, Pier Luigi
K1 biosimilar pharmaceuticals
K1 chronic
K1 infusion
K1 intravenous
K1 lymphocytic leukemia
K1 lymphoma
K1 non-Hodgkin
K1 rituximab
AB Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen (≤90 min) in clinical practice, published data on the safety of RI of CT-P10 in patients with NHL and CLL are limited. Hence, this study collected real-world safety and effectiveness data on RI-CT-P10 from the medical records of 196 patients with NHL or CLL in 10 European centers, 6 months after the date of the first RI (index date); the infusion-related reaction (IRR) rate was compared to previously published data. Ten percent (95% confidence interval 6%-15%; n = 20/196) of patients experienced an infusion-related reaction (IRR) on day 1-2 post-index, which was not significantly different (p = 0.45) to the IRR rate for rituximab described in a previous meta-analysis (8.8%). During the observation period, 2% of patients experienced grade 3-5 IRRs and 85% (n = 166) experienced an adverse event (non-IRR). The most common reason for discontinuation of first-line CT-P10 was planned treatment completion (81%; n = 158). Complete response and partial response to CT-P10 was observed in 74% (n = 142/192) and 22% (n = 42/192) of patients, respectively. The results of this real-world study demonstrate that the safety and effectiveness profile of RI-CT-P10 is similar to RI of reference rituximab and therefore support the current use of RI-CT-P10 in patients with NHL and CLL.
YR 2022
FD 2022-03-17
LK http://hdl.handle.net/10668/22028
UL http://hdl.handle.net/10668/22028
LA en
DS RISalud
RD Apr 9, 2025